1. Home
  2. MGNI vs ACAD Comparison

MGNI vs ACAD Comparison

Compare MGNI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGNI
  • ACAD
  • Stock Information
  • Founded
  • MGNI 2007
  • ACAD 1993
  • Country
  • MGNI United States
  • ACAD United States
  • Employees
  • MGNI N/A
  • ACAD N/A
  • Industry
  • MGNI Computer Software: Programming Data Processing
  • ACAD Biotechnology: Pharmaceutical Preparations
  • Sector
  • MGNI Technology
  • ACAD Health Care
  • Exchange
  • MGNI Nasdaq
  • ACAD Nasdaq
  • Market Cap
  • MGNI 2.5B
  • ACAD 2.9B
  • IPO Year
  • MGNI N/A
  • ACAD 2004
  • Fundamental
  • Price
  • MGNI $16.80
  • ACAD $17.81
  • Analyst Decision
  • MGNI Strong Buy
  • ACAD Buy
  • Analyst Count
  • MGNI 13
  • ACAD 19
  • Target Price
  • MGNI $17.88
  • ACAD $26.44
  • AVG Volume (30 Days)
  • MGNI 1.7M
  • ACAD 1.5M
  • Earning Date
  • MGNI 11-07-2024
  • ACAD 11-06-2024
  • Dividend Yield
  • MGNI N/A
  • ACAD N/A
  • EPS Growth
  • MGNI N/A
  • ACAD N/A
  • EPS
  • MGNI 0.12
  • ACAD 0.78
  • Revenue
  • MGNI $661,134,000.00
  • ACAD $929,236,000.00
  • Revenue This Year
  • MGNI $0.57
  • ACAD $37.34
  • Revenue Next Year
  • MGNI $10.41
  • ACAD $7.25
  • P/E Ratio
  • MGNI $139.30
  • ACAD $22.41
  • Revenue Growth
  • MGNI 8.71
  • ACAD 47.06
  • 52 Week Low
  • MGNI $8.38
  • ACAD $14.15
  • 52 Week High
  • MGNI $18.38
  • ACAD $32.59
  • Technical
  • Relative Strength Index (RSI)
  • MGNI 54.66
  • ACAD 54.79
  • Support Level
  • MGNI $15.93
  • ACAD $16.78
  • Resistance Level
  • MGNI $16.84
  • ACAD $17.60
  • Average True Range (ATR)
  • MGNI 0.63
  • ACAD 0.68
  • MACD
  • MGNI -0.22
  • ACAD -0.03
  • Stochastic Oscillator
  • MGNI 29.38
  • ACAD 45.21

About MGNI Magnite Inc.

Magnite is one of the largest supply-side platform providers, or SSP, in online advertising. The firm was previously named The Rubicon Project (an online ad exchange) and became Magnite after merging with Telaria (an SSP focused mainly on streaming video providers) in 2020. The firm also purchased another of the leading SSPs within the CTV market, SpotX, in 2021 for $1.2 billion, cementing its long-term focus on grabbing market share in this area. The firm generates nearly 45% of its revenue from the programmatic sale of CTV ad inventory, 35% from mobile online sites and apps, and the remaining from websites accessed via computer.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Share on Social Networks: